Although their mechanisms differ, both sGC modulators ultimately aim to induce vasodilation, lower blood pressure, and exert anti-inflammatory and antioxidant effects by increasing cGMP levels, offering novel insights into DKD treatment (Figure 1). The gene discussed is SGCB; the disease is diabetic kidney disease.